US Stock MarketDetailed Quotes

Theravance Biopharma (TBPH)

Watchlist
  • 17.020
  • -0.020-0.12%
Close Sep 18 16:00 ET
  • 17.020
  • 0.0000.00%
Post 19:30 ET
883.66MMarket Cap16.37P/E (TTM)

Theravance Biopharma (TBPH) Income Statement

Quarterly·All
YOY yoy
Hide blank lines yoy
Currency: USD
2026/Q2
2026/Q1
2025/Q4
2025/Q3
2025/Q2
2025/Q1
2024/Q4
2024/Q3
2024/Q2
2024/Q1
2023/Q4
2023/Q3
2023/Q2
2023/Q1
2022/Q4
2022/Q3
2022/Q2
2022/Q1
2021/Q4
2021/Q3
Total Revenue as Reported
-20.86%20.73M
+15.02%17.70M
+144.70%45.89M
+18.51%19.99M
+83.75%26.20M
+6.10%15.39M
+6.77%18.75M
+7.49%16.87M
+3.69%14.26M
+39.22%14.50M
+19.91%17.57M
+26.04%15.69M
+24.43%13.75M
-21.06%10.42M
-1.99%14.65M
-5.63%12.45M
-14.43%11.05M
-7.44%13.20M
-20.20%14.95M
-27.73%13.19M
Total Operating Revenue
-20.86%20.73M
+15.02%17.70M
+144.70%45.89M
+18.51%19.99M
+83.75%26.20M
+6.10%15.39M
+6.77%18.75M
+7.49%16.87M
+3.69%14.26M
+39.22%14.50M
+19.91%17.57M
+26.04%15.69M
+24.43%13.75M
-21.06%10.42M
-1.99%14.65M
-5.63%12.45M
-14.43%11.05M
-7.44%13.20M
-20.20%14.95M
-27.73%13.19M
Operating Expense
-34.69%18.89M
-21.03%23.55M
-7.42%25.88M
+1.16%26.45M
+7.07%28.92M
+15.99%29.82M
+17.43%27.95M
+6.91%26.14M
-5.90%27.01M
-23.83%25.71M
-25.79%23.81M
-6.47%24.45M
-7.84%28.70M
-17.86%33.76M
-39.18%32.08M
-59.80%26.14M
-59.56%31.15M
-58.13%41.10M
-44.53%52.74M
-31.45%65.04M
Selling and Admin Expenses
-23.08%14.18M
-3.54%17.72M
+0.10%18.52M
+8.64%18.33M
+8.06%18.43M
+9.72%18.37M
+19.42%18.50M
+4.54%16.88M
-11.53%17.06M
-12.72%16.74M
-7.41%15.49M
-0.83%16.14M
+18.84%19.28M
+7.52%19.18M
-22.23%16.73M
-23.58%16.28M
-37.44%16.22M
-41.60%17.84M
-28.10%21.52M
-22.55%21.30M
Research & Development
-55.08%4.71M
-49.10%5.83M
-22.14%7.36M
-12.47%8.11M
+5.38%10.49M
+27.70%11.45M
+13.71%9.45M
+11.51%9.27M
+5.61%9.95M
-38.46%8.97M
-45.84%8.31M
-15.77%8.31M
-36.85%9.43M
-37.33%14.57M
-50.85%15.35M
-77.44%9.87M
-70.79%14.92M
-65.60%23.25M
-52.08%31.23M
-35.08%43.74M
Operating Profit
+167.63%1.84M
+59.47%-5.85M
+317.51%20.01M
+30.40%-6.46M
+78.63%-2.73M
-28.79%-14.43M
-47.44%-9.20M
-5.88%-9.28M
+14.71%-12.75M
+51.98%-11.21M
+64.20%-6.24M
+36.03%-8.76M
+25.59%-14.95M
+16.35%-23.34M
+53.88%-17.43M
+73.59%-13.69M
+68.65%-20.10M
+66.74%-27.90M
+50.50%-37.80M
+32.33%-51.84M
Net Non-Operating Interest Income (Expense)
+339.04%3.49M
+917.91%3.01M
+1071.26%3.06M
+354.27%3.57M
+64.05%794.00K
-63.23%296.00K
-78.68%261.00K
-33.31%785.00K
-75.00%484.00K
-66.86%805.00K
-61.41%1.22M
-2.97%1.18M
+538.94%1.94M
+196.70%2.43M
+276.32%3.17M
+152.69%1.21M
+102.90%303.00K
+79.25%-2.51M
-107.15%-1.80M
+78.00%-2.30M
Non-Operating Interest Income
+139.26%3.49M
+220.87%3.01M
+302.54%3.64M
+192.51%4.14M
+29.17%1.46M
-34.52%939.00K
-51.06%904.00K
-20.77%1.42M
-54.95%1.13M
-51.86%1.43M
-50.38%1.85M
-35.24%1.79M
+2.62%2.50M
--2.98M
+1001.18%3.72M
--2.76M
+108.37%2.44M
----
-57.64%338.00K
----
Non-Operating Interest Expense
-100.00%0.00
-100.00%0.00
-9.49%582.00K
-9.05%573.00K
+2.95%663.00K
+2.23%643.00K
+3.21%643.00K
+3.45%630.00K
+13.38%644.00K
+14.36%629.00K
+13.27%623.00K
-60.58%609.00K
-73.42%568.00K
-78.11%550.00K
-74.26%550.00K
-32.88%1.55M
-81.60%2.14M
-79.25%2.51M
+108.77%2.14M
-80.11%2.30M
Other Income (Expense)
-113.47%-10.12M
---3.63M
--50.00M
----
+2646.15%75.14M
----
--0.00
---1.56M
-152.44%-2.95M
----
--0.00
----
+61.10%-1.17M
+83.12%-1.57M
+100.00%0.00
-100.06%-3.54M
-113.71%-3.01M
-156.35%-9.32M
+44.05%-18.37M
-113.09%-1.77M
Special Income (Charges)
-113.47%-10.12M
---3.63M
--0.00
+100.00%0.00
+2646.15%75.14M
--0.00
--0.00
---1.56M
-152.44%-2.95M
+100.00%0.00
--0.00
+100.00%0.00
+61.10%-1.17M
+83.12%-1.57M
+100.00%0.00
-100.06%-3.54M
---3.01M
---9.32M
-218.80%-18.37M
---1.77M
-Less:Restructuring and Mergern & Acquisition
--10.12M
--3.63M
----
----
--0.00
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
-100.00%0.00
-61.10%1.17M
-83.12%1.57M
-100.00%0.00
-71.26%509.00K
--3.01M
--9.32M
--18.37M
--1.77M
-Less:Impairment of Capital Assets
----
----
--0.00
-100.00%0.00
-100.00%0.00
----
--0.00
--1.56M
--2.95M
----
--0.00
--0.00
--0.00
----
----
----
----
----
----
----
-Less:Other Special Charges
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--3.03M
----
----
----
----
-Gain on Sale Of Business
----
----
----
----
--75.14M
----
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
-Gain on Sale of Property/Plant/Equipment
-100.00%0.00
----
--0.00
--0.00
--75.14M
----
--0.00
--0.00
--0.00
----
----
----
----
----
----
----
----
----
----
----
Pretax Profit
-106.54%-4.79M
+54.24%-6.47M
+917.41%73.07M
+71.26%-2.89M
+580.95%73.21M
-35.92%-14.14M
-78.21%-8.94M
-32.56%-10.05M
-7.29%-15.22M
+53.73%-10.40M
+64.82%-5.02M
+52.67%-7.58M
+37.77%-14.19M
+43.42%-22.48M
+75.40%-14.26M
+71.35%-16.02M
+56.68%-22.80M
+49.99%-39.74M
+31.02%-57.97M
+23.97%-55.92M
Tax
-93.97%1.11M
-174.96%-1.54M
+82.82%12.04M
-345.80%-6.50M
+1304.51%18.37M
-144.29%-559.00K
+88.55%6.59M
+93.56%2.65M
-10.29%1.31M
+419.49%1.26M
+116566.67%3.49M
--1.37M
+29260.00%1.46M
-175.38%-395.00K
+98.01%-3.00K
+100.00%0.00
+97.73%-5.00K
+130.84%524.00K
+98.28%-151.00K
-107.53%-7.00K
Net Profit
-110.76%-5.90M
+63.67%-4.93M
+493.02%61.02M
+128.47%3.62M
+431.75%54.84M
-16.42%-13.58M
-82.46%-15.53M
-41.88%-12.70M
-5.65%-16.53M
+47.19%-11.66M
+17.87%-8.51M
-100.98%-8.95M
-91.00%-15.65M
+14.87%-22.09M
+67.65%-10.36M
+2696.10%916.63M
+84.37%-8.19M
+67.44%-25.95M
+45.18%-32.03M
+52.06%-35.31M
Profit from Continuing Operations
-110.76%-5.90M
+63.67%-4.93M
+493.02%61.02M
+128.47%3.62M
+431.75%54.84M
-16.42%-13.58M
-82.46%-15.53M
-41.88%-12.70M
-5.65%-16.53M
+47.19%-11.66M
+40.31%-8.51M
+44.14%-8.95M
+31.36%-15.65M
+45.14%-22.09M
+75.34%-14.26M
+71.34%-16.02M
+56.51%-22.79M
+49.47%-40.26M
+23.16%-57.82M
+24.08%-55.91M
Net Income from Discontinuous Operations
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-84.90%3.89M
+4427.01%932.65M
--14.60M
--14.31M
--25.78M
--20.60M
Net Income to Parent Company
-110.76%-5.90M
+63.67%-4.93M
+493.02%61.02M
+128.47%3.62M
+431.75%54.84M
-16.42%-13.58M
-82.46%-15.53M
-41.88%-12.70M
-5.65%-16.53M
+47.19%-11.66M
+17.87%-8.51M
-100.98%-8.95M
-91.00%-15.65M
+14.87%-22.09M
+67.65%-10.36M
+2696.10%916.63M
+84.37%-8.19M
+67.44%-25.95M
+45.18%-32.03M
+52.06%-35.31M
Net Income to Common Stockholders
-110.76%-5.90M
+63.67%-4.93M
+493.02%61.02M
+128.47%3.62M
+431.75%54.84M
-16.42%-13.58M
-82.46%-15.53M
-41.88%-12.70M
-5.65%-16.53M
+47.19%-11.66M
+17.87%-8.51M
-100.98%-8.95M
-91.00%-15.65M
+14.87%-22.09M
+67.65%-10.36M
+2696.10%916.63M
+84.37%-8.19M
+67.44%-25.95M
+45.18%-32.03M
+52.06%-35.31M
Basic EPS
-110.09%-0.11
+62.96%-0.10
+487.10%1.20
+126.92%0.07
+420.59%1.09
-12.50%-0.27
-82.35%-0.31
-52.94%-0.26
-21.43%-0.34
+31.43%-0.24
-13.33%-0.17
-101.40%-0.17
-154.55%-0.28
-2.94%-0.35
+65.12%-0.15
+2629.17%12.14
+86.25%-0.11
+72.58%-0.34
+53.26%-0.43
+58.62%-0.48
Diluted EPS
-110.19%-0.11
+62.96%-0.10
+470.97%1.15
+126.92%0.07
+417.65%1.08
-12.50%-0.27
-82.35%-0.31
-52.94%-0.26
-21.43%-0.34
+31.43%-0.24
-13.33%-0.17
-101.40%-0.17
-154.55%-0.28
-2.94%-0.35
+65.12%-0.15
+2629.17%12.14
+86.25%-0.11
+72.58%-0.34
+53.26%-0.43
+58.62%-0.48
Deadline
Jun 30, 2026
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Accounting Standard
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
US_GAAP
2026/Q22026/Q12025/Q42025/Q32025/Q22025/Q12024/Q42024/Q32024/Q22024/Q12023/Q42023/Q32023/Q22023/Q12022/Q42022/Q32022/Q22022/Q12021/Q42021/Q3
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On September 1, U.S. Eastern Time, the U.S. military launched a new round of strikes against Iran in response to recent attempts by the Isla Show More